ArticleDiscover oncology2025
Development and validation of a novel disulfidptosis-related gene signature for prediction of survival and immune microenvironment in osteosarcoma by WGCNA analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disulfidptosis was reported to be associated with the malignant progression of various tumors. This study was aimed to investigate the prognostic significance of disulfidptosis-related genes (DRGs) in osteosarcoma (OS). Ten previously reported core disulfidptosis genes were used for consensus clustering and WGCNA analyses. A total of 338 disulfidptosis-related genes (DRGs) were identified. Then, uni-COX, LASSO and multi-COX analyses were conducted, identifying 5 prognosis-related DRGs (BTN3A1, CEBPA, KCNAB2, TBX21, and MYC). A prognostic DRGs risk signature based on the five genes were constructed and validated. OS patients were divided into high and low risk groups by risk scores. K-M plots and t-ROC curves showed that patients with high-risk scores had worse prognosis. Patients in the high-risk group had lower abundance of immune checkpoint-related genes, including CD274 (PD-L1), LAG3, PDCD1LG2 (PD-L2), and BTLA. Besides, patients in the high-risk group exhibited lower IC50 values for vorinostat, elesclomol, OSI-906, pyrimethamine, thapsigargin, and doxorubicin, but a higher IC50 value for cisplatin, compared to those in the low-risk group, indicating differential drug sensitivities. Additionally, analysis of immune checkpoint blockade (ICB) response revealed that patients in the high-risk group had a lower predicted response rate to immunotherapy. The mRNA expression levels of 4 DRGs including BTN3A1, KCNAB2, TBX21 and CEBPA in OS cells were significantly lower than those in hFOB1.19 cells. Subsequent experiments revealed that BTN3A1 protein was expressed at low levels in OS cells. Furthermore, overexpression of BTN3A1 significantly suppressed OS cell proliferation, migration, and invasion. In summary, we established a robust DRGs signature comprising BTN3A1, CEBPA, KCNAB2, TBX21, and MYC, which showed strong prognostic value and predictive potential for immune status and drug sensitivity in OS. Notably, functional experiments confirmed that BTN3A1 acted as a tumor suppressor in OS, highlighting it as a promising therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.